Feb 19 2010
- Cilag GmbH International to Terminate Collaboration
Janssen-Cilag International NV announced today that the Committee for
Medicinal Products for Human Use (CHMP) of the European Medicines Agency has
adopted a negative opinion on its Marketing Authorisation Application (MAA)
for the antibiotic ZEFTERA(TM) (ceftobiprole medocaril), for the treatment of
complicated skin and soft tissue infections.
Cilag GmbH International has given Basilea Pharmaceutica Ltd. notice of
termination of the worldwide License , Development and Co-Promotion Agreement
between the parties. The compound, including pending applications and
in-market products, will be transitioned back to Basilea under the terms of
the License Agreement.
Janssen-Cilag International NV and Cilag GmbH International are Johnson &
Johnson companies.
SOURCE Janssen-Cilag International NV